Heparan sulfate acts as a coreceptor that stabilizes many FGF–FGFR complexes. Adding heparin or changing its concentration can therefore alter apparent affinity, kinetics, and complex formation. When comparing candidates, protein lots, or publications, cofactor conditions should be standardized and reported. Heparin-free controls may be useful where relevant, but the optimal design depends on the ligand, receptor isoform, and assay geometry.

FGF ligands differ in receptor preference and dependence on heparan-sulfate cofactors. Validation with more than one ligand provides stronger evidence that the recombinant receptor retains a functional extracellular conformation and supports different assay designs. The page shows binding of the FGFR1 product to acidic FGF, basic FGF, and FGF-7 by SPR or BLI. These data support assay suitability but do not imply identical affinity or biology for all FGF ligands.

Alternative splicing within the FGFR1 extracellular region can alter ligand specificity, particularly around the third immunoglobulin-like domain. A recombinant protein may therefore represent only one receptor isoform and may not model every tissue context. Before starting a binding study, customers should confirm the amino-acid coverage, isoform, tag position, and whether the construct contains the domains required for the selected FGF ligand or antibody epitope.

Recombinant TREM2 proteins can be used as target antigens for antibody discovery, screening, and characterization. They support assays such as ELISA, SPR, and BLI to evaluate antibody binding, affinity, and kinetics. Depending on the experimental platform, researchers can select TREM2 proteins with different species or protein formats to support lead identification, characterization, and preclinical development.

TREM2 is expressed by tumor-associated macrophages (TAMs) and has been associated with immunosuppressive macrophage states in several solid tumors. TREM2 signaling can influence macrophage function and the tumor microenvironment, making it a potential target for cancer immunotherapy. Researchers are investigating whether TREM2-targeted approaches can reprogram tumor-associated macrophages and enhance responses to immune checkpoint therapies.